Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most frequent primary bone tumor that develops mainly during youth, the median age of diagnosis being 18 years. Despite improvement in osteosarcoma treatment, survival rate is only 30% after 5 years for patients with pulmonary metastases at diagnosis. This warrants exploration of new therapeutic options. The anti-bone resorption molecule receptor activator of NF-κB (RANK) is very promising, as it may block the vicious cycle between bone resorption and tumor proliferation that takes place during tumor development in bone site. The cDNA encoding murine RANK-Fc (mRANK-Fc) was administered by gene transfer using an amphiphilic polymer in a mouse model of osteolytic osteosarcoma. Clinical and bone microarchitecture variables were assessed by radiography and micro-CT analyses. In vitro experiments were designed to determine the mechanism of action of RANK-Fc on tumor cell proliferation (XTT assays), apoptosis (caspase activation), cell cycle distribution (fluorescence-activated cell sorting analysis), or gene expression (reverse transcription-PCR). RANK-Fc was effective in preventing the formation of osteolytic lesions associated with osteosarcoma development and in reducing the tumor incidence, the local tumor growth, and the lung metastases dissemination leading to a 3.9-fold augmentation of mice survival 28 days after implantation. On the contrary, mRANK-Fc did not prevent the development of nonosseous tumor nodules, suggesting that bone environment is necessary for mRANK-Fc therapeutic efficacy. Furthermore, mRANK-Fc has no direct activity on osteosarcoma cells in vitro. mRANK-Fc exerts an indirect inhibitory effect on osteosarcoma progression through inhibition of bone resorption. [Mol Cancer Ther 2008;7(10):3389–98]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of cancer cell migration and bone metastasis by RANKL.
Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., et al. (2006) · Nature · doi:10.1038/nature04524 · Cited by 796 · cited 1×
“shown that RANKL is implicated in the pathogenesis of bone metastasis at several levels: increased bone resorption as a result of excess RANKL results in the release of growth factors that facilitate tumor cell division and survival, and a recent study suggested a role for RANKL as a chemoattractant for certain cancer…”
BackgroundZhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Osteosarcoma: Anatomic and Histologic Variants
Klein, M. J., & Siegal, G. P. (2006) · American Journal of Clinical Pathology · doi:10.1309/uc6kqhld9lv2kenn · Cited by 386
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
Green, L. L. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00137-4 · Cited by 229 · cited 1×
“Denosumab was generated by immunizing the XenoMouse (33) with full-length human RANKL protein, producing a fully human IgG1 monoclonal antibody, which recognizes an epitope with a single amino acid difference between the mouse and the human sequences.”
MethodCharacterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor
Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., & Higashio, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5117 · Cited by 200 · cited 1×
“addition to containing four cysteine-rich domains, OPG also contains two death domains and a heparin-binding domain (14).”
BackgroundLamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181
Self-citationFully human therapeutic monoclonal antibodies.
Weiner, L. M. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000192105.24583.83 · Cited by 164
Cited by
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120
Self-citationQiao, B., Shui, W., Cai, L., Guo, S., & Jiang, D. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s77116 · Cited by 30
Metadata
- Authors
- Lamoureux, F., Picarda, G., Rousseau, J., Gourden, C., Battaglia, S., Charrier, C., Pitard, B., Heymann, D., & Rédini, F.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2008-10-01
- Volume
- 7
- Issue
- 10
- Pages
- 3389-3398
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2065426533
- Cited by
- 48
- References
- 9
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0497
- The paper
- Lamoureux, F., Picarda, G., Rousseau, J., Gourden, C., Battaglia, S., Charrier, C., Pitard, B., Heymann, D., & Rédini, F. (2008). Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.